{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-086174","form_type":"8-K","ticker":"CYRX","cik":"0001124524","company_name":"Cryoport, Inc.","filed_at":"2022-08-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:55.037021+00:00","generated_at":"2026-06-24T03:42:43.081420+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Cryoport Q2 revenue up 14% to $64.2M; net loss widens to $0.23/sh; guidance reaffirmed","bullets":["Revenue $64.2M (+14% YoY, +18% constant currency); Biopharma/Pharma $51.7M (+14%).","Net loss to common $11.2M ($0.23/sh) vs $7.4M ($0.16) in Q2 2021; GAAP net loss $9.2M.","Adjusted EBITDA $6.0M, flat YoY; gross margin 45.0%, steady YoY and up 224bps sequentially.","FY2022 revenue guidance reaffirmed at $260M-$265M; $33.3M share repurchase completed at avg $24.84.","Record 626 clinical trials supported; opened new Global Supply Chain Centers; closed three acquisitions in Europe."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-086174","json":"https://secwatch.observer/filing/0001104659-22-086174.json","markdown":"https://secwatch.observer/filing/0001104659-22-086174.md","text":"https://secwatch.observer/filing/0001104659-22-086174.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1124524/000110465922086174/0001104659-22-086174-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1124524/000110465922086174/tm2222628d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T03:42:43.081420+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}